BACKGROUND: Patients bridged to transplantation (TX) with the implantable left ventricular assist device (LVAD) may be at increased risk for the development of panel-reactive antibodies (PRA) during support. METHODS: To investigate that, we evaluated 60 patients who received the HeartMate LVAD at our institution, of whom 53 had PRA results available for analysis. T lymphocyte PRA levels were examined before LVAD, at the peak PRA level during LVAD support (PEAK), and just before TX. A PRA level more than 10% was considered indicative of sensitization against HLA antigens. RESULTS: The only factor that had a significant effect on PRA levels before LVAD was patient's sex (1.3% for men versus 7.4% for women; p = 0.005). During LVAD support, peak PRA levels increased significantly and the sex-associated differences were no longer evident (33.3% men, 34.3% women; not significant). At the time of TX, PRAs decreased to 10.9% (men) and 7.0% (women) (not significant). We examined the influence of blood products received before TX on PRA levels. Patients who received less than the median number of total units (<median) had lower peak PRA values (22.3% versus 49.2%; p = 0.01) and TX PRA values (3.5% versus 22.1%; p = 0.02) than those receiving more than the median (>median). When examined by the type of blood product, only the number of platelet transfusions significantly increased the peak PRA (<median: 24% versus >median: 46.9%; p = 0.03). Patients who received blood that was leukocyte-depleted tended to have lower TX PRA levels (2.9%) compared with those who did not (13.9%, p = 0.18). Forty-two patients were successfully bridged to TX, with three early and two late deaths after TX. Whereas 39 patients received transplants without intervention, 3 were treated by plasmapheresis with a 77% reduction in their HLA antibody levels at TX as measured by flow cytometry. CONCLUSIONS: Patients with the implantable LVAD are at significant risk for the development of anti-HLA antibodies during support. Although this sensitization is often transient, intervention using plasmapheresis may be useful for some patients.
BACKGROUND:Patients bridged to transplantation (TX) with the implantable left ventricular assist device (LVAD) may be at increased risk for the development of panel-reactive antibodies (PRA) during support. METHODS: To investigate that, we evaluated 60 patients who received the HeartMate LVAD at our institution, of whom 53 had PRA results available for analysis. T lymphocyte PRA levels were examined before LVAD, at the peak PRA level during LVAD support (PEAK), and just before TX. A PRA level more than 10% was considered indicative of sensitization against HLA antigens. RESULTS: The only factor that had a significant effect on PRA levels before LVAD was patient's sex (1.3% for men versus 7.4% for women; p = 0.005). During LVAD support, peak PRA levels increased significantly and the sex-associated differences were no longer evident (33.3% men, 34.3% women; not significant). At the time of TX, PRAs decreased to 10.9% (men) and 7.0% (women) (not significant). We examined the influence of blood products received before TX on PRA levels. Patients who received less than the median number of total units (<median) had lower peak PRA values (22.3% versus 49.2%; p = 0.01) and TX PRA values (3.5% versus 22.1%; p = 0.02) than those receiving more than the median (>median). When examined by the type of blood product, only the number of platelet transfusions significantly increased the peak PRA (<median: 24% versus >median: 46.9%; p = 0.03). Patients who received blood that was leukocyte-depleted tended to have lower TX PRA levels (2.9%) compared with those who did not (13.9%, p = 0.18). Forty-two patients were successfully bridged to TX, with three early and two late deaths after TX. Whereas 39 patients received transplants without intervention, 3 were treated by plasmapheresis with a 77% reduction in their HLA antibody levels at TX as measured by flow cytometry. CONCLUSIONS:Patients with the implantable LVAD are at significant risk for the development of anti-HLA antibodies during support. Although this sensitization is often transient, intervention using plasmapheresis may be useful for some patients.
Authors: George J Arnaoutakis; Timothy J George; Arman Kilic; Eric S Weiss; Stuart D Russell; John V Conte; Ashish S Shah Journal: J Thorac Cardiovasc Surg Date: 2011-08-11 Impact factor: 5.209
Authors: O Wever-Pinzon; J Stehlik; A G Kfoury; J V Terrovitis; N A Diakos; C Charitos; D Y Li; S G Drakos Journal: Pharmacol Ther Date: 2012-01-16 Impact factor: 12.310
Authors: H Haddad; D Isaac; J F Legare; P Pflugfelder; P Hendry; M Chan; B Cantin; N Giannetti; S Zieroth; M White; W Warnica; K Doucette; V Rao; A Dipchand; M Cantarovich; W Kostuk; R Cecere; E Charbonneau; H Ross; N Poirier Journal: Can J Cardiol Date: 2009-04 Impact factor: 5.223
Authors: Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris Journal: Transfusion Date: 2016-11-18 Impact factor: 3.157
Authors: R John; H Rajasinghe; J M Chen; A D Weinberg; P Sinha; S Itescu; K Lietz; D Mancini; M C Oz; C R Smith; E A Rose; N M Edwards Journal: Ann Surg Date: 2000-09 Impact factor: 12.969
Authors: Sarah B See; Kevin J Clerkin; Peter J Kennel; Feifan Zhang; Matthew P Weber; Kortney J Rogers; Debanjana Chatterjee; Elena R Vasilescu; George Vlad; Yoshifumi Naka; Susan W Restaino; Maryjane A Farr; Veli K Topkara; Paolo C Colombo; Donna M Mancini; P Christian Schulze; Bruce Levin; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2017-03-24 Impact factor: 10.247
Authors: Stavros G Drakos; Abdallah G Kfoury; John R Kotter; Bruce B Reid; Stephen E Clayson; Craig H Selzman; Josef Stehlik; Patrick W Fisher; Mario Merida; David D Eckels; Kim Brunisholz; Benjamin D Horne; Sandi Stoker; Dean Y Li; Dale G Renlund Journal: J Heart Lung Transplant Date: 2009-08 Impact factor: 10.247